Aduhelm
E24938
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
All labels observed (3)
| Label | Occurrences |
|---|---|
| aducanumab | 6 |
| Aduhelm canonical | 4 |
| aducanumab Phase 3 program | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T195378 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Aduhelm Context triple: [Biogen, hasProduct, Aduhelm]
-
A.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
D.
MCI-Shirley
MCI-Shirley is a medium- and minimum-security state prison for men located in Shirley, Massachusetts.
-
E.
Neuralink
Neuralink is a neurotechnology company developing implantable brain–computer interfaces aimed at enabling direct communication between the human brain and computers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Aduhelm Target entity description: Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
A.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
D.
MCI-Shirley
MCI-Shirley is a medium- and minimum-security state prison for men located in Shirley, Massachusetts.
-
E.
Neuralink
Neuralink is a neurotechnology company developing implantable brain–computer interfaces aimed at enabling direct communication between the human brain and computers.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
Alzheimer's disease treatment
ⓘ
drug ⓘ monoclonal antibody ⓘ |
| administrationFrequency | once every four weeks ⓘ |
| antibodyType | IgG1 ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| ATCCode | N06DX07 ⓘ |
| boxedWarning | amyloid-related imaging abnormalities ⓘ |
| clinicalTrial |
EMERGE (Study 302)
ⓘ
ENGAGE (Study 301) ⓘ |
| coDevelopedBy | Eisai ⓘ |
| commonAdverseEffect |
amyloid-related imaging abnormalities
ⓘ
confusion ⓘ diarrhea ⓘ falls ⓘ headache ⓘ |
| controversy |
accelerated approval despite mixed trial results
ⓘ
efficacy questioned by FDA advisory committee ⓘ high treatment cost ⓘ |
| developedBy | Biogen ⓘ |
| dosageForm | concentrate for solution for infusion ⓘ |
| drugClass |
anti-amyloid monoclonal antibody
ⓘ
disease-modifying therapy for Alzheimer's disease ⓘ |
| FDAApplicationNumber | BLA 761178 ⓘ |
| FDAApprovalDate | 2021-06-07 ⓘ |
| FDAApprovalType | accelerated approval ⓘ |
| firstInClass | first FDA-approved amyloid-targeting therapy for Alzheimer's disease ⓘ |
| halfLifeApproximate | 24 days ⓘ |
| hasGenericName |
aducanumab
ⓘ
linked to:
Aduhelm
|
| indication |
Alzheimer's disease
ⓘ
mild Alzheimer's disease dementia ⓘ mild cognitive impairment due to Alzheimer's disease ⓘ |
| initialDoseRegimen | titration to 10 mg/kg ⓘ |
| legalStatusInUnitedStates | prescription only ⓘ |
| marketingAuthorizationStatusInEU | application withdrawn ⓘ |
| mechanismOfAction |
binds aggregated forms of amyloid beta
ⓘ
reduces amyloid-beta plaques in the brain ⓘ |
| molecularType | human monoclonal antibody ⓘ |
| requiresGeneticConsideration | APOE ε4 carrier status for ARIA risk ⓘ |
| requiresMonitoring | brain MRI for ARIA ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| sponsorDecision | Biogen discontinued commercialization in the U.S. ⓘ |
| targetDiseaseStage | early Alzheimer's disease ⓘ |
| targets |
amyloid beta peptide
ⓘ
amyloid-beta plaques ⓘ |
| USMarketWithdrawalYear | 2024 ⓘ |
| withdrawnFromMarketInUnitedStates | true ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Aduhelm Description of subject: Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
Referenced by (11)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Aduhelm
subject linked to:
ARIA-H (amyloid-related imaging abnormalities with microhemorrhages and hemosiderin deposits)
linked to: Aduhelm
linked to: Aduhelm
linked to: Aduhelm
linked to: Aduhelm
linked to: Aduhelm
linked to: Aduhelm